A double-blind placebo-controlled case study of the use of donepezil to improve cognition in a schizoaffective disorder patient: Functional MRI correlates

Neurocase

Volumn 7, Issue 2, 2001, Pages 105-110

  Risch, S Craig ^a   McGurk, Susan ^b   Horner, Michael D ^a   Nahas, Ziad ^a   Owens, Susan D ^a   Molloy, Monica ^a   Gilliard, Cynthia ^a   Christie, Scott ^a   Markowitz, John S ^a   DeVane, C Lindsay ^a   Mintzer, Jacobo ^a   George, Mark S ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Cognition; Donepezil; Functional magnetic resonance imaging; Schizoaffective disorder

Indexed keywords

CLOZAPINE; DONEPEZIL; FLUOXETINE; LITHIUM; OLANZAPINE; PLACEBO; TIOTIXENE; VALPROIC ACID; VENLAFAXINE;

ADULT; ARTICLE; BASAL GANGLION; CASE REPORT; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE COURSE; DOUBLE BLIND PROCEDURE; FUNCTIONAL ASSESSMENT; HAMILTON SCALE; HOSPITALIZATION; HUMAN; MAINTENANCE THERAPY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTPATIENT CARE; PREFRONTAL CORTEX; QUALITY OF LIFE; RATING SCALE; SCHIZOIDISM; TREATMENT OUTCOME;

EID: 0035016524     PISSN: 13554794     EISSN: None     Source Type: Journal    
DOI: 10.1093/neucas/7.2.105     Document Type: Article

References (32)

1. Benton AL, Hamsher K, Sivan AB. Multilingual aphasia examination. 3rd ed. Iowa City, IA: AJA Associates, 1994.
2. Cassens G, Inglis AK, Appelbaum PS, Gutheil TG. Neuroleptics: effects of neuropsychological function in chronic schizophrenic patients. Schizophrenia Bulletin 1990; 16: 477-99.
3. Cleghom JM, Kaplan RD, Szechtman B, Szechtman H, Brown GM. Neuroleptic drug effects on cognitive function in schizophrenia. Schizophrenia Research 1990; 3: 211-9.
4. Cummings JL. Cholinesterase inhibitors: a new class of psychotropic compounds. American Journal of Psychiatry 2000; 157: 4-15.
5. Davidson M, Harvey P, Welsh KA, Powchik P, Putnam KM, Mohs RC. Cognitive functioning in late-life schizophrenia: a comparison of elderly schizophrenics patients and patients with Alzheimer's disease. American Journal of Psychiatry 1996; 153: 1274-9.
6. Friston KJ, Frith CD, Liddle PF. Investigating a network model of word generation with positron emission tomography. Proceedings of the Royal Society of London Series B: Biological Science 1991; 244: 101-6.
7. Frith CD, Friston KJ, Liddle PF, Frackowiak RS. A PET study of word finding. Neuropsychologia 1991; 29: 1137-48.
8. Fujii DEM, Ahmed I, Jokumsen M, Comptom JM. The effects of clozapine on cognitive function in treatment-resistant schizophrenic patients. Journal of Neuropsychiatry and Clinical Neuroscience 1997; 9: 240-5.
9. Gold JM, Harvey PD. Cognitive deficits in schizophrenia. Psychiatric Clinics of North America 1995; 16: 295-312.
10. Gold JM, Carpenter C, Randolph C, Goldberg TE, Weinberger DR. Auditory working memory and Wisconsin Card Sorting Test performance in schizophrenia. Archives of General Psychiatry 1997; 54: 159-65.
11. Goldberg TE, Weinberger DR, Berman KE, Piskin NH, Podd MH. Further evidence for dementia of the prefrontal type in schizophrenia? A controlled study of teaching the Wisconsin Card Sorting Test. Archives of General Psychiatry 1987; 44: 1008-14.
12. Goldman RS, Axelrod BN, Tandon R, Ribeiro SC, Craig K, Berent S. Neuropsychological prediction of treatment efficacy and one-year outcome in schizophrenia. Psychopathology 1993; 26: 122-6.
13. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? American Journal of Psychiatry 1996; 153: 321-30.
14. Green MF. Schizophrenia from a neurocognitive perspective. Boston, MA, USA: Allyn and Bacon 1998: 1-190.
15. Green MF, Marshall BD Jr, Wirshing WC, Ames D, Marder SR, McGurk S et al. Does risperidone improve verbal working memory in treatment resistant schizophrenia? American Journal of Psychiatry 1997; 154: 799-804.
16. Hagger C, Buckley P, Kenny JT, Friedman I, Ubogy D, Meltzer HY. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biological Psychiatry 1993; 34: 702-12.
17. Heaton R, Paulsen JS, McAdams LA, Kuck J, Zisook S, Braff D et al. Neuropsychological deficits in schizophrenics: relationship to age, chronicity and dementia. Archives of General Psychiatry 1994; 51: 469-76.
18. Hoff AL, Riordan H, O'Donnell DW, Morris L, DeLisi CE. Neuropsychological functioning of first-episode schizophreniform patients. American Journal of Psychiatry 1992; 149: 898-903.
19. Hoff AL, Faustman WO, Wieneke M, Espinoza S, Costa M, Wolkowitz O et al. The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic patients. Neuropsychopharmacology 1996; 15: 361-9.
20. Keefe, RSE, Silva SG, Perkins DO, Lieberman JA. The effects of atypical antipsychotics on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophrenia Bulletin 1999; 25: 201-22.
21. Kern RS, Green MF, Marshall BD Jr, Wirshing WC, Wirshing D, McGurk S et al. Risperidone vs. haloperidol on reaction time, manual dexterity, and motor learning in treatment-resistant schizophrenic patients. Biological Psychiatry 1998; 44: 726-32.
22. Lysaker P, Bell M, Beam-Goulet J. Wisconsin Card Sorting Test and work performance in schizophrenia. Psychiatric Research 1995; 56: 45-51.
23. McGurk SR, Green MF, Wirshing WC, Ames D, Marshall BD, Marder SR et al. The effects of risperidone vs. haloperidol on cognitive functioning in treatment resistant schizophrenia: The Trail Making Test. CNS Spectrums 1997; 2: 60-4.
24. Meltzer HY, McGurk S. The effect of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophrenia Bulletin 1999; 25: 223-55.
25. Palmer BW, Heaton RK, Paulsen IS. Is it possible to be schizophrenic yet neuropsychologically normal? Neuropsychology 1997; 11: 437-46.
26. Park S, Holzman PS. Schizophrenics show spatial working memory deficits. Archives of General Psychiatry 1992; 49: 975-82.
27. Paulsen JS, Heaton RK, Sadek JR, Perry W, Delis DD, Braff D et al. The nature of learning and memory impairments in schizophrenia. Journal of the International Neuropsychological Society 1995; 1: 88-99.
28. Powchick P, Davidson M, Haroutunian V, Gabriel SM, Purohit P, Perl DP et al. Postmortem studies in schizophrenia. Schizophrenia Bulletin 1998; 24: 325-41.
29. Saykin AI, Shtasel DI, Gur RE, Kester DB, Moxley LH, Stafaniak P et al. Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Archives of General Psychiatry 1994; 51: 124-31.
30. Schlosser R, Hutchinson M, Joseffer S, Rusinek H, Saarimaki A, Stevenson J et al. Functional magnetic resonance imaging of human brain activity in a verbal fluency task. Journal of Neurology, Neurosurgery and Psychiatry 1998; 64: 492-8.
31. Stone M, Gabrieli JDE, Stebbins GT, Sullivan EV. Working and strategic memory deficits in schizophrenia. Neuropsychology 1998; 12: 278-88.
32. Zahn TP, Pickar D, Haier RJ. Effects of clozapine, fluphenazine and placebo on reaction time measures of attention and sensory dominance in schizophrenia. Schizophrenia Research 1994; 15: 133-44.